News for Taysha Gene Therapies, Inc. (TSHA)

Taysha's cash runway extends to Q4 2026, but likely capital raises could dilute shareholders, adding to downside risk. Click here to read why TSHA is a Sell.

DALLAS, April 04, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. ( TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on adva

S&P 500 and Nasdaq had their worst quarters since 2022 due to concerns over Trump's economic policy and new tariffs. The S&P 500 dropped 4.6% and Nasdaq fell 10.5%. Tech stocks like Tesla and Nvidia saw major declines. Energy sector gained 9.3%. Goldman Sachs raised the recession probability to 35% amid ongoing uncertainty.

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Monday. The Dow traded up 0.30% to 41,710.68 while the NASD...

DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. ( TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on

Feb 26, 2025 / 01:30PM GMTOperator Ladies and gentlemen, good morning and welcome to the Taysha Gene Therapies full year 2024 conference call. (Operator Instruc

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Conference Call February 26, 2025 8:30 AM ETCompany ParticipantsHayleigh Collins - Director &...

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of 12.50% and 6.42%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patient

Taysha Gene Therapies Inc (TSHA) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $2.31 million, and the ea

**media[544469]**

On December 31, 2024, RTW INVESTMENTS, LP (Trades, Portfolio) executed a significant transaction involving Taysha Gene Therapies Inc (TSHA). The firm reduced it

Significant Transaction by FMR LLC (Trades, Portfolio) On December 31, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, executed a notable transa

DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. ( TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advan

Taysha Gene Therapies offers hope for Rett syndrome with innovative treatment, strong trial results, and promising regulatory path. See more on TSHA stock here.

**media[504880]**

**media[485338]**

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Thursday. Shares of Hillenbrand, Inc. HI rose sharply in today's session follo...

U.S. stock futures were higher this morning, with the Dow futures gaining more than 50 points on Thursday. Shares of Advance Auto Parts, Inc. AAP fell sharply ...